6 new drugs approved clinically to develop treatment of seizure asleep disease, cancer, stroke medium

Transfer from Pharmaceutical Mission China's State Drug Administration Drug Review Center (CDE) recently announced that a number of new drugs have been approved for clinical trials.
These products in the study involving adaptive narcissism, cancer, stroke, hepatitis B, epilepsy and so on, including Takeda developed the first-in-class OX2R agonists, and then Ding Pharmaceuticals from Incyte introduced anti-PD-1 monoclonal antibodies, as well as Shanghai Medicine from Shuntian Pharmaceuticals (Lumosa Therapeutics) introduced new stroke drugs and so on.
the product in an antho-section of this article.
1, Takeda: TAK-994 tablets of adaptive disorders: TAK-994 is an oral drug-given selective orrexin-2 subject (OX2R) agitant, this product in China has obtained clinical trials implied permission to develop for seizure sleeping sickness, for the first time approved clinical in China.
is a neurotransmitter that is often considered the primary regulator of the sleep-wake cycle.
onset dne disease is a long-term neurological disease caused by the loss of neurons in the brain that produce appetite.
that OX2R agitants may replace endoensitive appetite peptides and activate signaling path path paths that promote sobriety.
, according to Takeda, the company is currently conducting a Phase 2 clinical trial on TAK-994.
2, Incyte/Redding Medicine: INCMGA00012 Injection Adaptation: Inconsecretible, locally relapsed or metastatic tube squamous cell carcinoma INCMGA0012, developed by MacroGenics, is an anti-PD-1 monoclonal antibody that has been licensed to Incyte in 2017.
July 2019, Reding Pharmaceuticals obtained exclusive development and commercial licensing of the drug in Greater China (Chinese mainland, Hong Kong, Macau and Taiwan, the same as between 2019.
, INCMGA0012 has been approved in China for three clinical trials involving cancers such as non-small cell lung cancer, endometrial cancer, and stomach cancer or gastroesophageal conjunctivitis cancer.
INCMGA0012 has obtained an implied license for clinical trials in China to develop non-surgical, locally relapsed or metastatic squamous cell carcinoma that has not previously underwent systemic chemotherapy.
3, Lumosa Therapeutics/Shanghai Pharmaceuticals: Injection LT3001 Adaptation: Acute ischemic stroke LT3001 is a new drug for acute stroke treatment combining targeted thrombosis and neuroproteative functions, and Shanghai Pharmaceuticals last year reached a partnership with Lumosa Therapeutics to obtain exclusive rights in the development, production and sale of the LT3001 project in Chinese mainland.
According to public information, previous studies have shown that the LT3001 has great potential to extend the treatment window without increasing the risk of bleeding, while removing free fundamentals, protecting brain nerve cells, and has the potential advantage of reducing refill damage and cerebral edema and improving prognosis.
the product has been approved for clinical trials in China and is intended to be developed for acute ischemic stroke for the first time in China.
4, SK Life Science: Cenobamate Tablet Adaptation: Cenobamate, an anti-epileptic drug developed by SK Life Science of Korea, has been approved by the FDA to treat partial seizure epilepsy in adults, and Arvelle owns the exclusive development and commercialization rights of the drug in Europe.
the drug reduces the repeated release of electrical impulses by nerve cells by suppressing voltage gated sodium currents and positively regulating GABAA's activity through isomer action.
the product has been granted implied permission in clinical trials in China to develop a partial seizure for the treatment of epilepsy in adult patients.
5, Janssen Pharmaceuticals: JNJ-73763989 Injection Adaptation: 1) Chronic Hepatitis B Virus (HBV) Infection; A new hepatitis treatment class 1 drug developed by Johnson's Janssen Pharmaceuticals has been granted a clinical trial in China to develop adaptations including 1) chronic hepatitis B virus (HBV) infection;
According to the clinictrials website, the product has been registered for six clinical trials worldwide, four of which are Phase 2 clinical, including Phase 2 studies on the treatment of chronic hepatitis B virus infection in different combinations with the selective HBV replication inhibitor JNJ-56136379.
6, Guangshengtang Pharmaceuticals: GST-HG121 adaptive: This product is intended for the treatment of chronic hepatitis B (HBV) GST-HG121 is a new treatment of hepatitis B drugs, hepatitis B surface antigen (HBsAg) inhibitors.
According to the announcement of Guangshengtang Pharmaceuticals, the basic research of this product has shown that it has an innovative therapeutic mechanism to inhibit HBsAg, which can effectively inhibit HBsAg expression, reduce the surface antigen titration of hepatitis B, and hopefully greatly improve the antigen transvulsion rate of hepatitis B surface, restore the immuno-surveillance mechanism, and help improve the cure rate.
the product has been approved for clinical trials in China to be developed for the treatment of chronic hepatitis B.
References: China's State Drug Administration Drug Review Center. Retrieved Sep 7,2020, from the official websites and public press releases of the companies follow the WeChat Public Number of Pharmaceutical Mingkangde